Researchers are looking for ways to make “cold” tumors “hot”, making them visible to the immune system and therefore more likely to respond to immunotherapy. Click to learn about strategies being tested in clinical trials.
Learn how oncolytic viruses work and how to find MBC clinical trials studying this new type of treatment.
Click to learn about biomarkers and targeted therapies for triple-negative MBC.
Read about immune checkpoint inhibitors approved and in clinical trials for MBC.
Understand more about the change in approval for Atezolizumab (Tecentriq®) for TNBC.
Click here for MBC-related research and reports from ASCO 2021.
What is the difference between CAR T-cell therapy, TCR therapy, TIL therapy, NK cell therapy, and Bria-IMT? Learn more here.
What is the difference between CAR T-cell therapy, TCR therapy, TIL therapy, NK cell therapy, and Bria-IMT? Learn more here.
Learn more about immunotherapy resistance and current clinical trials on metastatic breast cancer immunotherapy.
